Skip to main content
Erschienen in: Journal of Endocrinological Investigation 4/2016

01.04.2016 | Original Article

How to define hypogonadism? Results from a population of men consulting for sexual dysfunction

verfasst von: G. Rastrelli, G. Corona, M. Tarocchi, E. Mannucci, M. Maggi

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The thresholds for testost erone (T) and the symptoms required for defining late onset hypogonadism (LOH) are under debate. The aims of the study are: (1) to verify the association between total and calculated free T (cfT) and sexual symptoms and (2) to identify thresholds for total and calculated free T to discriminate symptomatic from asymptomatic men.

Methods

A consecutive series of 4890 men attending the outpatient clinic for sexual dysfunction was retrospectively studied. Biochemical parameters were collected. The relationships between symptoms and total or calculated free T were evaluated as LOESS curves.

Results

Severe impairment in morning erections, low libido and ED were reported by 14.6, 2.7 and 60.2 %, respectively. Simultaneous presence of severe ED and impaired morning erections or low desire was reported by 12.7 and 1.9 %, respectively. Severely reduced desire and morning erections were complained of by 1.0 %. The simultaneous presence of the three severe sexual symptoms was reported by 0.8 %. Receiver operating characteristic (ROC) curve analysis showed that the highest accuracy for total T and cfT in detecting subjects with two symptoms was observed for reduced morning erections and desire (area under the ROC curve [AUC] = 0.670 ± 0.04 and 0.747 ± 0.04, for total T and cfT, respectively, both p < 0.0001). The addition of the third symptom, ED, further improved the accuracy (AUC = 0.681 ± 0.05 and 0.784 ± 0.04, for total T and cfT, respectively, both p < 0.0001). The assessment of the Youden index showed that the best thresholds for detecting men with androgen deficiency-related symptoms are 10.4 nmol/L for total T and ranges 225–260 pmol/L for cfT.

Conclusions

The simultaneous presence of reduced morning erections and desire is the cluster of symptoms that, along with total T < 10.4 nmol/L or cfT <225 pmol/L, defines LOH in a specific, evidence-based manner.
Literatur
1.
Zurück zum Zitat Smith KW, Feldman HA, McKinlay JB (2000) Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 53:703–711CrossRef Smith KW, Feldman HA, McKinlay JB (2000) Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 53:703–711CrossRef
2.
Zurück zum Zitat Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C (2006) Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60:762–769CrossRefPubMedPubMedCentral Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C (2006) Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60:762–769CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Corona G, Rastrelli G, Maggi M (2013) Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 27:557–579CrossRefPubMed Corona G, Rastrelli G, Maggi M (2013) Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 27:557–579CrossRefPubMed
4.
Zurück zum Zitat Iglesias P, Prado F, Macías MC, Guerrero MT, Muñoz A, Ridruejo E, Tajada P, García-Arévalo C, Díez JJ (2014) Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome. J Endocrinol Invest 37:135–141CrossRefPubMed Iglesias P, Prado F, Macías MC, Guerrero MT, Muñoz A, Ridruejo E, Tajada P, García-Arévalo C, Díez JJ (2014) Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome. J Endocrinol Invest 37:135–141CrossRefPubMed
5.
Zurück zum Zitat Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M (2012) How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 14:251–259CrossRefPubMedPubMedCentral Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M (2012) How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 14:251–259CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Lenzi A, Balercia G, Bellastella A, Colao A, Fabbri A, Foresta C, Galdiero M, Gandini L, Krausz C, Lombardi G, Lombardo F, Maggi M, Radicioni A, Selice R, Sinisi AA, Forti G (2009) Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest 32:934–938CrossRefPubMed Lenzi A, Balercia G, Bellastella A, Colao A, Fabbri A, Foresta C, Galdiero M, Gandini L, Krausz C, Lombardi G, Lombardo F, Maggi M, Radicioni A, Selice R, Sinisi AA, Forti G (2009) Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest 32:934–938CrossRefPubMed
7.
Zurück zum Zitat Morley JE, Haren MT, Kim MJ, Kevorkian R, Perry HM 3rd (2005) Testosterone, aging and quality of life. J Endocrinol Invest 28(3 Suppl):76–80PubMed Morley JE, Haren MT, Kim MJ, Kevorkian R, Perry HM 3rd (2005) Testosterone, aging and quality of life. J Endocrinol Invest 28(3 Suppl):76–80PubMed
8.
Zurück zum Zitat Vignozzi L, Corona G, Petrone L, Filippi S, Morelli AM, Forti G, Maggi M (2005) Testosterone and sexual activity. J Endocrinol Invest 28(3 Suppl):39–44PubMed Vignozzi L, Corona G, Petrone L, Filippi S, Morelli AM, Forti G, Maggi M (2005) Testosterone and sexual activity. J Endocrinol Invest 28(3 Suppl):39–44PubMed
9.
Zurück zum Zitat Francomano D, Fattorini G, Gianfrilli D, Paoli D, Sgrò P, Radicioni A, Romanelli F, Di Luigi L, Gandini L, Lenzi A, Aversa A (2015) Acute endothelial response to testosterone gel administration in men with severe hypogonadism and its relationship to androgen receptor polymorphism: a pilot study. J Endocrinol Invest. [Epub ahead of print] Francomano D, Fattorini G, Gianfrilli D, Paoli D, Sgrò P, Radicioni A, Romanelli F, Di Luigi L, Gandini L, Lenzi A, Aversa A (2015) Acute endothelial response to testosterone gel administration in men with severe hypogonadism and its relationship to androgen receptor polymorphism: a pilot study. J Endocrinol Invest. [Epub ahead of print]
10.
Zurück zum Zitat Camozzi V, Bonanni G, Frigo A, Piccolo M, Ferasin S, Zaninotto M, Boscaro M, Luisetto G (2015) Effect of a single injection of testosterone enanthate on 17β estradiol and bone turnover markers in hypogonadal male patients. J Endocrinol Invest 38:389–397CrossRefPubMed Camozzi V, Bonanni G, Frigo A, Piccolo M, Ferasin S, Zaninotto M, Boscaro M, Luisetto G (2015) Effect of a single injection of testosterone enanthate on 17β estradiol and bone turnover markers in hypogonadal male patients. J Endocrinol Invest 38:389–397CrossRefPubMed
11.
Zurück zum Zitat Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A (2014) Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 37:401–411CrossRefPubMed Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A (2014) Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 37:401–411CrossRefPubMed
12.
Zurück zum Zitat Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC, International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU); European Academy of Andrology (EAA), American Society of Andrology (ASA) (2009) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 30:1–9CrossRefPubMed Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC, International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU); European Academy of Andrology (EAA), American Society of Andrology (ASA) (2009) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 30:1–9CrossRefPubMed
13.
Zurück zum Zitat Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536–2559CrossRefPubMed Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536–2559CrossRefPubMed
14.
Zurück zum Zitat Buvat J, Maggi M, Guay A, Torres LO (2013) Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 10:245–284CrossRefPubMed Buvat J, Maggi M, Guay A, Torres LO (2013) Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 10:245–284CrossRefPubMed
15.
Zurück zum Zitat Miner MM, Seftel AD (2007) Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead? Int J Clin Pract 61:622–632CrossRefPubMed Miner MM, Seftel AD (2007) Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead? Int J Clin Pract 61:622–632CrossRefPubMed
16.
Zurück zum Zitat Morales A, Schulman CC, Tostain J, Wu FCW (2006) Testosterone deficiency syndrome (TDS) needs to be named appropriately–the importance of accurate terminology. Eur Urol 50:407–409CrossRefPubMed Morales A, Schulman CC, Tostain J, Wu FCW (2006) Testosterone deficiency syndrome (TDS) needs to be named appropriately–the importance of accurate terminology. Eur Urol 50:407–409CrossRefPubMed
17.
Zurück zum Zitat Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, EMAS Group (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123–135CrossRefPubMed Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, EMAS Group (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123–135CrossRefPubMed
18.
Zurück zum Zitat Rastrelli G, Carter EL, Ahern T, Finn JD, Antonio L, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Keevil B, Maggi M, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC (2015) Development of and recovery from secondary hypogonadism in ageing men: prospective results from the EMAS. J Clin Endocrinol Metab 100:3172–3182CrossRefPubMed Rastrelli G, Carter EL, Ahern T, Finn JD, Antonio L, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Keevil B, Maggi M, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC (2015) Development of and recovery from secondary hypogonadism in ageing men: prospective results from the EMAS. J Clin Endocrinol Metab 100:3172–3182CrossRefPubMed
19.
Zurück zum Zitat Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Male Aging Study Group (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93:2737–2745CrossRefPubMed Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Male Aging Study Group (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93:2737–2745CrossRefPubMed
20.
Zurück zum Zitat Maseroli E, Corona G, Rastrelli G, Lotti F, Cipriani S, Forti G, Mannucci E, Maggi M (2015) Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med 12:956–965CrossRefPubMed Maseroli E, Corona G, Rastrelli G, Lotti F, Cipriani S, Forti G, Mannucci E, Maggi M (2015) Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med 12:956–965CrossRefPubMed
21.
Zurück zum Zitat Zitzmann M, Faber S, Nieschlag E (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91:4335–4343CrossRefPubMed Zitzmann M, Faber S, Nieschlag E (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91:4335–4343CrossRefPubMed
22.
Zurück zum Zitat Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M (2006) ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 3:706–715CrossRefPubMed Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M (2006) ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 3:706–715CrossRefPubMed
23.
Zurück zum Zitat Petrone L, Mannucci E, Corona G, Bartolini M, Forti G, Giommi R, Maggi M (2003) Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 15:210–220CrossRefPubMed Petrone L, Mannucci E, Corona G, Bartolini M, Forti G, Giommi R, Maggi M (2003) Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 15:210–220CrossRefPubMed
24.
Zurück zum Zitat Corona G, Ricca V, Bandini E, Rastrelli G, Casale H, Jannini EA, Sforza A, Forti G, Mannucci E, Maggi M (2012) SIEDY scale 3, a new instrument to detect psychological component in subjects with erectile dysfunction. J Sex Med 9:2017–2026CrossRefPubMed Corona G, Ricca V, Bandini E, Rastrelli G, Casale H, Jannini EA, Sforza A, Forti G, Mannucci E, Maggi M (2012) SIEDY scale 3, a new instrument to detect psychological component in subjects with erectile dysfunction. J Sex Med 9:2017–2026CrossRefPubMed
25.
Zurück zum Zitat Corona G, Rastrelli G, Balercia G, Sforza A, Forti G, Mannucci E, Maggi M (2011) Perceived reduced sleep-related erections in subjects with erectile dysfunction: psychobiological correlates. J Sex Med 8:1780–1788CrossRefPubMed Corona G, Rastrelli G, Balercia G, Sforza A, Forti G, Mannucci E, Maggi M (2011) Perceived reduced sleep-related erections in subjects with erectile dysfunction: psychobiological correlates. J Sex Med 8:1780–1788CrossRefPubMed
26.
Zurück zum Zitat Corona G, Rastrelli G, Ricca V, Jannini EA, Vignozzi L, Monami M, Sforza A, Forti G, Mannucci E, Maggi M (2013) Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. J Sex Med 10:1074–1089CrossRefPubMed Corona G, Rastrelli G, Ricca V, Jannini EA, Vignozzi L, Monami M, Sforza A, Forti G, Mannucci E, Maggi M (2013) Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. J Sex Med 10:1074–1089CrossRefPubMed
27.
Zurück zum Zitat Maseroli E, Rastrelli G, Corona G, Boddi V, Amato AM, Mannucci E, Forti G, Maggi M (2014) Gynecomastia in subjects with sexual dysfunction. J Endocrinol Invest 37:525–532CrossRefPubMed Maseroli E, Rastrelli G, Corona G, Boddi V, Amato AM, Mannucci E, Forti G, Maggi M (2014) Gynecomastia in subjects with sexual dysfunction. J Endocrinol Invest 37:525–532CrossRefPubMed
28.
Zurück zum Zitat Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672CrossRefPubMed Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672CrossRefPubMed
29.
Zurück zum Zitat Fox J (2002) Nonparametric regression: appendix to an R and S-PLUS companion to applied regression, January 2002 Fox J (2002) Nonparametric regression: appendix to an R and S-PLUS companion to applied regression, January 2002
30.
Zurück zum Zitat Schisterman EF, Perkins NJ, Liu A, Bondell H (2005) Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples”. Epidemiology 16:73–81CrossRefPubMed Schisterman EF, Perkins NJ, Liu A, Bondell H (2005) Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples”. Epidemiology 16:73–81CrossRefPubMed
31.
Zurück zum Zitat Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M (2013) IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 10:579–588CrossRefPubMed Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M (2013) IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 10:579–588CrossRefPubMed
32.
Zurück zum Zitat Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L, Maggi M (2007) Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 30:880–888CrossRefPubMed Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L, Maggi M (2007) Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 30:880–888CrossRefPubMed
33.
Zurück zum Zitat Bellastella A, Esposito D, Conte M, Ruocco G, Bellastella G, Sinisi AA, Pasquali D (2005) Sexuality in aging male. J Endocrinol Invest 28(11 Suppl Proceedings):55–60 Bellastella A, Esposito D, Conte M, Ruocco G, Bellastella G, Sinisi AA, Pasquali D (2005) Sexuality in aging male. J Endocrinol Invest 28(11 Suppl Proceedings):55–60
34.
Zurück zum Zitat Corona G, Rastrelli G, Balercia G, Lotti F, Sforza A, Monami M, Forti G, Mannucci E, Maggi M (2012) Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med 9:1669–1680CrossRefPubMed Corona G, Rastrelli G, Balercia G, Lotti F, Sforza A, Monami M, Forti G, Mannucci E, Maggi M (2012) Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med 9:1669–1680CrossRefPubMed
35.
Zurück zum Zitat Corona G, Giorda CB, Cucinotta D, Guida P, Nada E, SUBITO-DE study group (2013) The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J Endocrinol Invest 36:864–868PubMed Corona G, Giorda CB, Cucinotta D, Guida P, Nada E, SUBITO-DE study group (2013) The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J Endocrinol Invest 36:864–868PubMed
36.
Zurück zum Zitat Maggi M, Filippi S, Ledda F, Magini A, Forti G (2000) Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol 143:143–154CrossRefPubMed Maggi M, Filippi S, Ledda F, Magini A, Forti G (2000) Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol 143:143–154CrossRefPubMed
37.
Zurück zum Zitat Chrysant SG (2015) Antihypertensive therapy causes erectile dysfunction. Curr Opin Cardiol 30:383–390PubMed Chrysant SG (2015) Antihypertensive therapy causes erectile dysfunction. Curr Opin Cardiol 30:383–390PubMed
38.
Zurück zum Zitat Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC, International Society of Andrology (ISA), International Society for the Study of the Aging Male (ISSAM), European Association of Urology (EAU) (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48:1–4CrossRefPubMed Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC, International Society of Andrology (ISA), International Society for the Study of the Aging Male (ISSAM), European Association of Urology (EAU) (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48:1–4CrossRefPubMed
39.
Zurück zum Zitat Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, Santi D, Maggi M (2015) Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest 38:103–112CrossRefPubMedPubMedCentral Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, Santi D, Maggi M (2015) Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest 38:103–112CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Vermeulen A, Verdonck G (1992) Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 74:939–942CrossRefPubMed Vermeulen A, Verdonck G (1992) Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 74:939–942CrossRefPubMed
41.
Zurück zum Zitat Radicioni A, Lenzi A, Spaziani M, Anzuini A, Ruga G, Papi G, Raimondo M, Foresta C (2013) A multicenter evaluation of immunoassays for follicle-stimulating hormone, luteinizing hormone and testosterone: concordance, imprecision and reference values. J Endocrinol Invest 36:739–744CrossRefPubMed Radicioni A, Lenzi A, Spaziani M, Anzuini A, Ruga G, Papi G, Raimondo M, Foresta C (2013) A multicenter evaluation of immunoassays for follicle-stimulating hormone, luteinizing hormone and testosterone: concordance, imprecision and reference values. J Endocrinol Invest 36:739–744CrossRefPubMed
42.
Zurück zum Zitat Lee DM, O’Neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N, Tajar A, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, Wu FC, EMAS study group (2009) The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl 32:11–24CrossRefPubMed Lee DM, O’Neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N, Tajar A, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, Wu FC, EMAS study group (2009) The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl 32:11–24CrossRefPubMed
Metadaten
Titel
How to define hypogonadism? Results from a population of men consulting for sexual dysfunction
verfasst von
G. Rastrelli
G. Corona
M. Tarocchi
E. Mannucci
M. Maggi
Publikationsdatum
01.04.2016
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 4/2016
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0425-1

Weitere Artikel der Ausgabe 4/2016

Journal of Endocrinological Investigation 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.